Table 4

Determinants of mRS score reduction (n=216)

mRS score reduction (shift analysis)
UnivariableMultivariable*
OR95% CIP valueOR95% CIP value
Age (years)
 <60RefRef
 ≥600.390.22 to 0.690.0010.310.15 to 0.660.003
Sex
 FemaleRefRef
 Male1.110.67 to 1.860.682
Race
 African-AmericanRefRef
 Caucasian1.570.84 to 2.920.157
 Others0.860.41 to 1.800.688
Comorbidities
 Smoking0.630.25 to 1.580.323
 Atrial fibrillation1.380.69 to 2.790.365
 Prior anticoagulation1.420.53 to 3.790.483
 Coronary artery disease1.000.52 to 1.920.990
 Congestive heart failure0.790.40 to 1.570.500
 Diabetes mellitus0.440.26 to 0.740.0020.470.23 to 0.940.032
 Hypertension0.560.29 to 1.060.0740.660.29 to 1.490.315
 Hyperlipidaemia1.040.61 to 1.770.880
 Previous stroke1.110.59 to 2.080.745
 Chronic kidney disease1.010.52 to 1.930.987
Admission NIHSS (one unit)0.890.86 to 0.93<0.0010.910.87 to 0.96<0.001
Large vessel occlusion0.340.19 to 0.59<0.0010.520.23 to 1.200.124
Stroke aetiology
 CardioembolismRefRef
 CS/ESUS1.230.59 to 2.560.5761.190.52 to 2.730.685
 Large-artery atherosclerosis0.980.36 to 2.670.9640.890.29 to 2.770.843
 Small-vessel occlusion2.920.99 to 8.590.0522.980.71 to 12.440.131
Labs
 NLR (one unit)0.920.86 to 0.980.0070.950.91 to 0.990.008
 D dimer (µ100 ng/mL)0.990.99 to 1.000.0810.990.98 to 1.000.093
 Absolute lymphocyte (1000/µL)1.000.99 to 1.010.804
 Platelets1.001.00 to 1.000.536
IV tPA1.600.86 to 2.970.137
Thrombectomy1.040.55 to 1.980.898
sICH0.230.07 to 0.760.0150.180.04 to 0.730.016
  • Univariable and multivariable mixed effects ordinal logistic regression analyses were done to test for the impact of several determinants on a reduction of mRS score and a decrease in disability. Variables that had a p<0.1 were included in the final multivariable model.

  • *The results after multiple imputation using chained equations to handle missing data.

  • CS/ESUS, cryptogenic stroke/embolic stroke of undetermined source; NIHSS, National Institutes of Health Stroke Scale; NLR, neutrophil–lymphocyte ratio; sICH, symptomatic intracranial haemorrhage; IV tPA, intravenous tissue plasminogen activator.